Patents by Inventor Ian Foltz

Ian Foltz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8444981
    Abstract: There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.
    Type: Grant
    Filed: March 16, 2010
    Date of Patent: May 21, 2013
    Assignee: Amgen Inc.
    Inventors: Hailing Hsu, Ian Foltz, Taruna Arora, Frederick W. Jacobsen
  • Publication number: 20130101589
    Abstract: Polypeptides are provided. Antibodies or antigen binding domains are provided which bind such polypeptides. Also provided are methods of obtaining an antibody that binds tumor necrosis factor (TNF)-related apoptosis-inducing ligand (“TRAIL”) Receptor-2 (TR-2) comprising administering at least one of such polypeptides to an animal and obtaining an antibody that binds TR-2 from the animal. Antibodies reactive with TR-2 are provided. Also provided are cells producing antibodies reactive with TR-2, pharmaceutical compositions comprising antibodies reactive with TR-2, methods using antibodies reactive with TR-2, and kits comprising antibodies reactive with TR-2. Also provided are methods of decreasing or preventing binding of an antibody to TR-2 by administering such a polypeptide.
    Type: Application
    Filed: September 7, 2012
    Publication date: April 25, 2013
    Inventors: Brian Gliniak, Xiao-Dong Yang, Sharon Wong-Madden, Ian Foltz, Xiao Feng, Alison Fitch, Stephen Foster, Randal R. Ketchem
  • Patent number: 8398975
    Abstract: Targeted binding agents, such antibodies directed to the antigen ?V?6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen ?V?6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.
    Type: Grant
    Filed: May 18, 2010
    Date of Patent: March 19, 2013
    Assignee: MedImmune Limited
    Inventors: Julie Rinkenberger, Ian Foltz, Avril Alfred, Simon Thomas Barry, Vahe Bedian
  • Patent number: 8350011
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen-binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-ErbB2 antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Grant
    Filed: August 2, 2007
    Date of Patent: January 8, 2013
    Assignee: MedImmune Limited
    Inventors: Susan Ann Cartlidge, Jianying Dong, Mark Hickinson, Ian Foltz, Jaspal Singh Kang
  • Publication number: 20120328616
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling.
    Type: Application
    Filed: June 1, 2012
    Publication date: December 27, 2012
    Applicant: AMGEN INC.
    Inventors: YANG LI, Jennitte STEVENS, Chadwick Terence KING, Ian FOLTZ, Gunasekaran KANNAN, Junming YIE, Shaw-Fen Sylvia HU
  • Publication number: 20120251555
    Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
    Type: Application
    Filed: November 29, 2011
    Publication date: October 4, 2012
    Inventors: Gregory M. Landes, Francine Chen, Binyam Bezabeh, Ian Foltz, Kam Fai Tse, Michael Jeffers, Mehdi Mesri, Gary Starling, Peter Mezes, Nikolia Khramtsov
  • Publication number: 20120244167
    Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.
    Type: Application
    Filed: April 27, 2012
    Publication date: September 27, 2012
    Applicants: WARNER-LAMBERT COMPANY LLC, AMGEN FREMONT INC.
    Inventors: Vahe Bedian, Madhav Narasimha Devalaraja, Ian Foltz, Mary Haak-Frendscho, Sirid-Aimée Kellermann, Joseph Edwin Low, James Leslie Mobley
  • Publication number: 20120195905
    Abstract: The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of DLL-4 and as diagnostics.
    Type: Application
    Filed: April 13, 2012
    Publication date: August 2, 2012
    Applicant: Medlmmune, LLC
    Inventors: Vahe Bedian, David Jenkins, Ian FOLTZ
  • Publication number: 20120183561
    Abstract: There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.
    Type: Application
    Filed: March 22, 2012
    Publication date: July 19, 2012
    Applicant: Amgen Inc.
    Inventors: Hailing HSU, Ian Foltz, Taruna Arora, Frederick W. Jacobsen
  • Publication number: 20120177662
    Abstract: There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.
    Type: Application
    Filed: March 22, 2012
    Publication date: July 12, 2012
    Applicant: Amgen Inc.
    Inventors: Hailing HSU, Ian Foltz, Taruna Arora, Frederick W. Jacobsen
  • Patent number: 8192738
    Abstract: The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of DLL4 and as diagnostics.
    Type: Grant
    Filed: September 18, 2009
    Date of Patent: June 5, 2012
    Assignee: MedImmune, LLC
    Inventors: Vahe Bedian, David Jenkins, Ian Foltz
  • Patent number: 8188249
    Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: May 29, 2012
    Assignees: Amgen Fremont Inc., Warner-Lambert Company LLC
    Inventors: Vahe Bedian, Madhav Narasimha Devalaraja, Ian Foltz, Mary Haak-Frendscho, Sirid-Aimee Kellermann, Joseph Edwin Low, James Leslie Mobley
  • Publication number: 20120114667
    Abstract: The invention relates to targeted binding agents against ?5?1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to ?5?1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of ?5?1 and as diagnostics.
    Type: Application
    Filed: December 21, 2009
    Publication date: May 10, 2012
    Applicant: MEDIMMUNE LIMITED
    Inventors: Catherine Anne Eberlein, Ian Foltz, Jaspal Singh Kang, Jane Kendrew, Avril Alfred, Simon Thomas Barry
  • Publication number: 20120107324
    Abstract: The invention relates to targeted binding agents against ?5?1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to ?5?1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of ?5?1 and as diagnostics.
    Type: Application
    Filed: December 21, 2009
    Publication date: May 3, 2012
    Inventors: Catherine Anne Eberlein, Ian Foltz, Jaspal Singh Kang, Jane Kendrew, Avril Alfred, Simon Thomas Barry
  • Patent number: 8067544
    Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
    Type: Grant
    Filed: March 19, 2004
    Date of Patent: November 29, 2011
    Assignee: Curagen Corporation
    Inventors: Gregory M. Landes, Francine Chen, Binyam Bezabeh, Ian Foltz, Kam Fai Tse, Michael Jeffers, Mehdi Mesri, Gary Starling, Peter Mezes, Nikolia Khramtsov
  • Patent number: 7994302
    Abstract: The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, there are provided human monoclonal antibodies directed to IL-13. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided. Additionally, methods of using these antibodies to treat patients are also provided. Additionally, IL-13 dependent biomarkers and methods of their identification and use are also provided.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: August 9, 2011
    Assignee: Amgen Inc.
    Inventors: Ian Foltz, Raffaella Faggioni, Giorgio Senaldi, Kathy Manchulenko, Jaspal S. Kang, Palaniswami Rathanaswami, Kiran Ahluwalia, Orit Foord, Scott Klakamp
  • Publication number: 20110150888
    Abstract: The invention relates to monoclonal antibodies that bind hepcidin and methods of making and using such antibodies. Also provided are methods of treating hepcidin-related disorders.
    Type: Application
    Filed: April 28, 2009
    Publication date: June 23, 2011
    Applicant: AMGEN INC.
    Inventors: Ian Foltz, Michael Gallo, Keegan Cooke, Randal R. Ketchem, Christopher Mehlin
  • Publication number: 20110135657
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4.
    Type: Application
    Filed: December 3, 2010
    Publication date: June 9, 2011
    Applicant: AMGEN INC.
    Inventors: Shaw-Fen Sylvia Hu, Ian Foltz, Chadwick Terence King, Yang Li, Taruna Arora
  • Publication number: 20110020360
    Abstract: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
    Type: Application
    Filed: February 18, 2010
    Publication date: January 27, 2011
    Applicant: ASTRAZENECA AB
    Inventors: NAOMI LAING, JASPAL SINGH KANG, IAN FOLTZ, GADI GAZIT-BOMSTEIN, XIAO-DANG YANG, SUE A. CARTLIDGE, DAVID CHARLES BLAKEY
  • Publication number: 20100330103
    Abstract: Targeted binding agents, such antibodies directed to the antigen ?V?6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen ?V?6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.
    Type: Application
    Filed: May 18, 2010
    Publication date: December 30, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Julie RINKENBERGER, Ian FOLTZ, Avril ALFRED, Simon Thomas BARRY, Vahe BEDIAN